logo
logo

Vero Biotech Receives Funding From Mvm Partners To Accelerate Growth

Dec 21, 2021•over 3 years ago
Atlanta

Description

VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the funding of up to $100 million in a Series E financing round led by MVM Partners (MVM), which included participation from a strategic investor. Funds from the round will support the expanded commercialization of the GENOSYL® Delivery System (GENOSYL® DS).

Company Information

Company

Vero Biotech

Location

Atlanta, Georgia, United States

About

VERO Biotech Inc. (formerly known as GeNO LLC) is focused on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with a variety of pulmonary and cardiac diseases. VERO Biotech is dedicated to improving the lives of patients by leading the development of innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever inhaled nitric oxide treatment is needed.